ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 249 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $10,946,000 | -61.5% | 788,585 | -22.2% | 0.12% | -51.2% |
| Q4 2021 | $28,458,000 | -21.8% | 1,014,185 | -5.2% | 0.25% | -20.5% |
| Q3 2021 | $36,379,000 | -17.5% | 1,070,285 | -0.9% | 0.32% | -12.2% |
| Q2 2021 | $44,108,000 | -1.8% | 1,079,485 | -3.3% | 0.36% | -6.2% |
| Q1 2021 | $44,926,000 | -44.5% | 1,115,885 | -18.4% | 0.38% | -41.4% |
| Q4 2020 | $80,894,000 | +14.8% | 1,368,063 | -5.6% | 0.66% | -0.5% |
| Q3 2020 | $70,458,000 | -7.5% | 1,448,863 | -8.0% | 0.66% | -9.2% |
| Q2 2020 | $76,193,000 | +63.7% | 1,574,890 | -6.0% | 0.73% | +31.0% |
| Q1 2020 | $46,548,000 | +4.4% | 1,675,590 | +12.4% | 0.56% | +39.4% |
| Q4 2019 | $44,607,000 | +31.0% | 1,490,881 | +35.2% | 0.40% | +32.2% |
| Q3 2019 | $34,062,000 | +56.5% | 1,102,321 | +144.6% | 0.30% | +80.2% |
| Q2 2019 | $21,769,000 | – | 450,700 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |